{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T02:02:36Z","timestamp":1790301756274,"version":"4.1.0"},"reference-count":27,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,9,4]],"date-time":"2018-09-04T00:00:00Z","timestamp":1536019200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008373","name":"Takeda Pharmaceutical Company Limited","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008373","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","prd-journal.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Parkinsonism & Related Disorders"],"published-print":{"date-parts":[[2019,3]]},"DOI":"10.1016\/j.parkreldis.2018.08.024","type":"journal-article","created":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T04:36:41Z","timestamp":1535776601000},"page":"146-152","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":47,"special_numbering":"C","title":["Rasagiline monotherapy in early Parkinson's disease: A phase 3, randomized study in Japan"],"prefix":"10.1016","volume":"60","author":[{"given":"Nobutaka","family":"Hattori","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Takeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinichi","family":"Takeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akira","family":"Nishimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tadayuki","family":"Kitagawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideki","family":"Mochizuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Nagai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryosuke","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9996","key":"10.1016\/j.parkreldis.2018.08.024_bib1","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1016\/S0140-6736(14)61393-3","article-title":"Parkinson's disease","volume":"386","author":"Kalia","year":"2015","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.parkreldis.2018.08.024_bib2","article-title":"Alzheimer's disease facts and figures","volume":"10","year":"2014","journal-title":"Alzheimer's Dementia"},{"issue":"Suppl 2","key":"10.1016\/j.parkreldis.2018.08.024_bib3","first-page":"S47","article-title":"Drug selection and timing of initiation of treatment in early Parkinson's disease","volume":"64","author":"Schapira","year":"2008","journal-title":"Ann. Neurol."},{"issue":"9","key":"10.1016\/j.parkreldis.2018.08.024_bib4","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1111\/j.1742-1241.2010.02371.x","article-title":"How should we treat a patient with early Parkinson's disease?","volume":"64","author":"Tsouli","year":"2010","journal-title":"Int. J. Clin. Pract."},{"issue":"8","key":"10.1016\/j.parkreldis.2018.08.024_bib5","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1001\/archneur.64.8.1083","article-title":"Treatment options in the modern management of Parkinson disease","volume":"64","author":"Schapira","year":"2007","journal-title":"Arch. Neurol."},{"issue":"1","key":"10.1016\/j.parkreldis.2018.08.024_bib6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.5607\/en.2011.20.1.1","article-title":"MAO-inhibitors in Parkinson's disease","volume":"20","author":"Riederer","year":"2011","journal-title":"Exp. Neurobiol."},{"issue":"3","key":"10.1016\/j.parkreldis.2018.08.024_bib7","first-page":"467","article-title":"Rasagiline - a novel MAO B inhibitor in Parkinson's disease therapy","volume":"3","author":"Lecht","year":"2007","journal-title":"Therapeut. Clin. Risk Manag."},{"issue":"11","key":"10.1016\/j.parkreldis.2018.08.024_bib8","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.5692\/clinicalneurol.53.1346","article-title":"[Treatment & management guidelines 2011 for Parkinson disease]","volume":"53","author":"Takeda","year":"2013","journal-title":"Rinsho Shinkeigaku"},{"issue":"13","key":"10.1016\/j.parkreldis.2018.08.024_bib10","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1056\/NEJMoa0809335","article-title":"A double-blind, delayed-start trial of rasagiline in Parkinson's disease","volume":"361","author":"Olanow","year":"2009","journal-title":"N. Engl. J. Med."},{"issue":"12","key":"10.1016\/j.parkreldis.2018.08.024_bib11","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1001\/archneur.59.12.1937","article-title":"A controlled trial of rasagiline in early Parkinson disease: the tempo study","volume":"59","author":"Parkinson Study Group","year":"2002","journal-title":"Arch. Neurol."},{"issue":"2","key":"10.1016\/j.parkreldis.2018.08.024_bib12","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1001\/archneur.62.2.241","article-title":"A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study","volume":"62","author":"Parkinson Study Group","year":"2005","journal-title":"Arch. Neurol."},{"issue":"9463","key":"10.1016\/j.parkreldis.2018.08.024_bib13","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1016\/S0140-6736(05)71083-7","article-title":"Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given once daily, study): a randomised, double-blind, parallel-group trial","volume":"365","author":"Rascol","year":"2005","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.parkreldis.2018.08.024_bib14","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1002\/mds.20764","article-title":"Rasagiline improves quality of life in patients with early Parkinson's disease","volume":"21","author":"Biglan","year":"2006","journal-title":"Mov. Disord."},{"issue":"3","key":"10.1016\/j.parkreldis.2018.08.024_bib15","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1212\/WNL.0b013e31827deb74","article-title":"The spectrum of nonmotor symptoms in early Parkinson disease","volume":"80","author":"Khoo","year":"2013","journal-title":"Neurology"},{"issue":"15","key":"10.1016\/j.parkreldis.2018.08.024_bib16","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1002\/mds.22340","article-title":"Movement disorder society-sponsored revision of the unified Parkinson's disease rating scale (MDS-UPDRS): scale presentation and clinimetric testing results","volume":"23","author":"Goetz","year":"2008","journal-title":"Mov. Disord."},{"issue":"3","key":"10.1016\/j.parkreldis.2018.08.024_bib17","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1002\/mdc3.12058","article-title":"MDS-UPDRS Japanese validation study group, official Japanese version of the movement disorder society-unified Parkinson's disease rating scale: validation against the original English version","volume":"1","author":"Kashihara","year":"2014","journal-title":"Mov.Disord. clin. pract."},{"issue":"9","key":"10.1016\/j.parkreldis.2018.08.024_bib18","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1002\/mds.20213","article-title":"Movement disorder society task force on rating scales for Parkinson's disease, movement disorder society task force report on the Hoehn and Yahr staging scale: status and recommendations","volume":"19","author":"Goetz","year":"2004","journal-title":"Mov. Disord."},{"issue":"5","key":"10.1016\/j.parkreldis.2018.08.024_bib19","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1093\/ageing\/26.5.353","article-title":"The Parkinson's Disease Questionnaire (PDQ-39): development and validation of a Parkinson's disease summary index score","volume":"26","author":"Jenkinson","year":"1997","journal-title":"Age Ageing"},{"issue":"13","key":"10.1016\/j.parkreldis.2018.08.024_bib20","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1002\/mds.25945","article-title":"The prevalence of Parkinson's disease: a systematic review and meta-analysis","volume":"29","author":"Pringsheim","year":"2014","journal-title":"Mov. Disord."},{"issue":"12","key":"10.1016\/j.parkreldis.2018.08.024_bib21","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1016\/j.parkreldis.2015.10.006","article-title":"Minimal clinically important difference on the Motor Examination part of MDS-UPDRS","volume":"21","author":"Horvath","year":"2015","journal-title":"Park. Relat. Disord."},{"issue":"5","key":"10.1016\/j.parkreldis.2018.08.024_bib22","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1002\/mds.26960","article-title":"Minimal clinically important differences for the experiences of daily living parts of movement disorder society-sponsored unified Parkinson's disease rating scale","volume":"32","author":"Horvath","year":"2017","journal-title":"Mov. Disord."},{"key":"10.1016\/j.parkreldis.2018.08.024_bib23","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.phrs.2013.05.005","article-title":"Rasagiline in Parkinson's disease: a review based on meta-analysis of clinical data","volume":"74","author":"M\u00ednguez-M\u00ednguez","year":"2013","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.parkreldis.2018.08.024_bib24","article-title":"Monoamine oxidase B inhibitors for early Parkinson's disease","volume":"3","author":"Turnbull","year":"2005","journal-title":"Cochrane Database Syst. Rev."},{"issue":"5","key":"10.1016\/j.parkreldis.2018.08.024_bib25","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1097\/WNF.0000000000000239","article-title":"A randomized double-blind placebo-controlled phase III trial of selegiline monotherapy for early Parkinson disease","volume":"40","author":"Mizuno","year":"2017","journal-title":"Clin. Neuropharmacol."},{"issue":"4","key":"10.1016\/j.parkreldis.2018.08.024_bib26","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1002\/mds.26124","article-title":"Effects of rasagiline on the progression of nonmotor scores of the MDS-UPDRS","volume":"30","author":"Poewe","year":"2015","journal-title":"Mov. Disord."},{"issue":"4","key":"10.1016\/j.parkreldis.2018.08.024_bib27","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1002\/mds.22343","article-title":"Double-blind trial of levodopa\/carbidopa\/entacapone versus levodopa\/carbidopa in early Parkinson's disease","volume":"24","author":"Hauser","year":"2009","journal-title":"Mov. Disord."},{"issue":"4","key":"10.1016\/j.parkreldis.2018.08.024_bib28","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1007\/s00702-013-1114-x","article-title":"Efficacy of levodopa\/carbidopa\/entacapone versus levodopa\/carbidopa in patients with early Parkinson's disease experiencing mild wearing-off: a randomised, double-blind trial","volume":"121","author":"Tolosa","year":"2014","journal-title":"J. Neural. Transm."}],"container-title":["Parkinsonism & Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1353802018303833?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1353802018303833?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,8]],"date-time":"2019-08-08T15:41:08Z","timestamp":1565278868000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1353802018303833"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3]]},"references-count":27,"alternative-id":["S1353802018303833"],"URL":"https:\/\/doi.org\/10.1016\/j.parkreldis.2018.08.024","relation":{},"ISSN":["1353-8020"],"issn-type":[{"value":"1353-8020","type":"print"}],"subject":[],"published":{"date-parts":[[2019,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Rasagiline monotherapy in early Parkinson's disease: A phase 3, randomized study in Japan","name":"articletitle","label":"Article Title"},{"value":"Parkinsonism & Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.parkreldis.2018.08.024","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}